No Fast Track For Lecanemab In EU Disappoints Eisai
Approval Could Come March 2024
Executive Summary
Despite being hailed as a potential breakthrough for Alzheimer’s, the EMA will not fast-track lecanemab, underscoring differences with the FDA’s frequent use of accelerated pathways.
You may also be interested in...
Leqembi Set For Japan Launch After Twisty Pricing Process
Eisai/Biogen's Alzheimer's drug will be launched in Japan on 20 December with a lower price premium than Eisai was negotiating for after back-and-forth reimbursement negotiations, and strict use and monitoring restrictions.
Leqembi Set For Japan Launch After Twisty Pricing Process
Eisai/Biogen's Alzheimer's drug will be launched in Japan on 20 December with a lower price premium than Eisai was negotiating for after back-and-forth reimbursement negotiations, and strict use and monitoring restrictions.
Eisai’s Leqembi Launch Bodes Well For Biogen In A Pivotal Year
Eisai said the US launch of Alzheimer’s therapy Leqembi following accelerated approval is going well, which is welcome news for partner Biogen as it brings on a new CEO and recovers from a failed Aduhelm launch.